Anti-neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo


Por: Manso, C, Querol, L, Lleixa, C, Poncelet, M, Mekaouche, M, Vallat, JM, Illa, I, Devaux, JJ

Publicada: 3 jun 2019
Resumen:
Neurofascin-155 (Nfasc155) is an essential glial cell adhesion molecule expressed in paranodal septate-like junctions of peripheral and central myelinated axons. The genetic deletion of Nfasc155 results in the loss of septate-like junctions and in conduction slowing. In humans, IgG4 antibodies against Nfasc155 are implicated in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). These antibodies are associated with an aggressive onset, a refractoriness to intravenous immunoglobulin, and tremor of possible cerebellar origin. Here, we examined the pathogenic effects of patient-derived anti-Nfasc155 IgG4. These antibodies did not inhibit the ability of Nfasc155 to complex with its axonal partners contactin-1 and CASPR1 or induce target internalization. Passive transfer experiments revealed that IgG4 antibodies targeted Nfasc155 on Schwann cell surfaces, and diminished Nfasc155 protein levels and prevented paranodal complex formation in neonatal animals. In adult animals, chronic intrathecal infusions of antibodies also induced the loss of Nfasc155 and of paranodal specialization and resulted in conduction alterations in motor nerves. These results indicate that anti-Nfasc155 IgG4 antibodies perturb conduction in the absence of demyelination, validating the existence of paranodopathy. These results also shed light on the mechanisms regulating protein insertion at paranodes.

Filiaciones:
Manso, C:
 Aix Marseille Univ, CNRS, CRN2M UMR1286, Marseille, France

 Univ Bordeaux, Interdisciplinary Inst Neurosci, UMR5297, Bordeaux, France

Querol, L:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Neuromuscular Dis Unit, Barcelona, Spain

 Ctr Invest Red Enfermedades Raras CIBERER, Madrid, Spain

Lleixa, C:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Neuromuscular Dis Unit, Barcelona, Spain

 Ctr Invest Red Enfermedades Raras CIBERER, Madrid, Spain

Poncelet, M:
 Montpellier Univ, Hop Gui de Chauliac, INSERM U1051, Inst Neurosci Montpellier, 80 Ave Augustin Fliche, F-34295 Montpellier 5, France

Mekaouche, M:
 Aix Marseille Univ, CNRS, CRN2M UMR1286, Marseille, France

 Aix Marseille Univ, CNRS, INP UMR7051, Marseille, France

Vallat, JM:
 Univ Hosp, Natl Reference Ctr Rare Peripheral Neuropathies, Limoges, France

 Univ Hosp, Dept Neurol, Limoges, France

Illa, I:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Neuromuscular Dis Unit, Barcelona, Spain

 Ctr Invest Red Enfermedades Raras CIBERER, Madrid, Spain

Devaux, JJ:
 Aix Marseille Univ, CNRS, CRN2M UMR1286, Marseille, France

 Montpellier Univ, Hop Gui de Chauliac, INSERM U1051, Inst Neurosci Montpellier, 80 Ave Augustin Fliche, F-34295 Montpellier 5, France
ISSN: 00219738
Editorial
AMER SOC CLINICAL INVESTIGATION INC, 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 129 Número: 6
Páginas: 2222-2236
WOS Id: 000470082800017
ID de PubMed: 30869655
imagen Bronze, Green Published

MÉTRICAS